Biotech’s fundraising and M&A bonanza continues to boost the specialist funds invested in this exciting growth industry. One healthcare trust benefiting from the boom is RTW Biotech Opportunities (LON:RTW). The London-listed fund has announced that private portfolio holding Avere Therapeutics is to merge with publicly-listed NextCure (NASDAQ:NXTC). Avere is the fourth private portfolio company RTW … Continue reading RTW Biotech Opportunities delivers fourth reverse merger of 2026